CTMX CytomX Therapeutics Forecast, Technical & Fundamental Analysis
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment... Show more
CTMX is expected to report earnings to fall 21.11% to -7 cents per share on November 10
Q3'26
Est.
$-0.07
Q2'26
Missed
by $0.01
Q1'26
Beat
by $0.02
Q4'25
Missed
by $0.08
Q3'25
Missed
by $0.04
The last earnings report on August 06 showed earnings per share of -9 cents, missing the estimate of -7 cents. With 1.21M shares outstanding, the current market capitalization sits at 769.18M.
A.I. Advisor
published General Information
General Information
an oncology-base biopharmaceutical company, which focuses on developing probody therapeutics for the treatment of cancer
A.I.dvisor indicates that over the last year, CTMX has been loosely correlated with MLEC. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if CTMX jumps, then MLEC could also see price increases.
CTMX in downward trend: price expected to drop as it breaks its higher Bollinger Band on September 01, 2026
CTMX broke above its upper Bollinger Band on September 01, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 36 similar instances where the stock broke above the upper band. In of the 36 cases the stock fell afterwards. This puts the odds of success at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CTMX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 01, 2026. You may want to consider a long position or call options on CTMX as a result. In of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for CTMX just turned positive on September 01, 2026. Looking at past instances where CTMX's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .
CTMX moved above its 50-day moving average on September 01, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CTMX crossed bullishly above the 50-day moving average on September 08, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where CTMX advanced for three days, in of 235 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 161 cases where CTMX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CTMX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.546) is normal, around the industry mean (20.490). P/E Ratio (18.167) is within average values for comparable stocks, (28.270). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.510). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (35.336) is also within normal values, averaging (444.384).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CTMX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
